Literature DB >> 9585725

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.

T Spencer1, J Biederman, T Wilens, J Prince, M Hatch, J Jones, M Harding, S V Faraone, L Seidman.   

Abstract

OBJECTIVE: The authors assessed the experimental noradrenergic compound tomoxetine as an alternative treatment for adult attention deficit hyperactivity disorder (ADHD).
METHOD: They conducted a double-blind, placebo-controlled, crossover study of tomoxetine in 22 adults with well-characterized ADHD.
RESULTS: Treatment with tomoxetine at an average oral dose of 76 mg/day was well tolerated. Drug-specific improvement in ADHD symptom was highly significant overall and sufficiently robust to be detectable in a parallel-groups comparison restricted to the first 3 weeks of the protocol. Eleven of 21 patients showed improvement after receiving tomoxetine, compared with only two of 21 patients who improved after receiving placebo. Significant tomoxetine-associated improvement was noted on neuropsychological measures of inhibitory capacity from Stroop tests.
CONCLUSIONS: This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated. These promising results provide support for further studies of tomoxetine over an extended period of treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585725     DOI: 10.1176/ajp.155.5.693

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  77 in total

Review 1.  Adult attention deficit hyperactivity disorder.

Authors:  S V Faraone; M T Tsuang
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

2.  An atomoxetine tutorial.

Authors:  David Feifel
Journal:  Psychiatry (Edgmont)       Date:  2007-08

Review 3.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 4.  Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder.

Authors:  Craig W Berridge; David M Devilbiss
Journal:  Biol Psychiatry       Date:  2010-09-26       Impact factor: 13.382

5.  Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members.

Authors:  Ronald C Kessler; Lenard A Adler; Michael J Gruber; Chaitanya A Sarawate; Thomas Spencer; David L Van Brunt
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

6.  Managing ADHD in children, adolescents, and adults with comorbid anxiety in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 7.  Assessment and management of attention-deficit hyperactivity disorder in adults.

Authors:  Margaret Weiss; Candice Murray
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

8.  Noradrenergic modulation of risk/reward decision making.

Authors:  David R Montes; Colin M Stopper; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

9.  Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex.

Authors:  Lori A Newman; Jenna Darling; Jill McGaughy
Journal:  Psychopharmacology (Berl)       Date:  2008-06-22       Impact factor: 4.530

Review 10.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.